4/A: Adaptive Biotechnologies CFO Sells Shares to Cover Tax Obligations

Kyle Piskel, CFO of Adaptive Biotechnologies, sold 1,929 shares of common stock on May 16, 2025, to cover tax withholding obligations related to the vesting of RSUs.

Summary

• On May 16, 2025, Kyle Piskel, the Chief Financial Officer of Adaptive Biotechnologies Corp, sold 1,929 shares of the company's common stock.
• The sale was executed at a price of $8.89 per share.
• This transaction was conducted to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• Following the transaction, Piskel directly owns 269,581 shares of Adaptive Biotechnologies Corp.
• The sale was mandated by the issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the Reporting Person.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing related to a stock sale for tax purposes. It doesn't inherently indicate positive or negative sentiment, but is a neutral event.

Management Comments

• The sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the Reporting Person.

Industry Context

Sales of shares to cover tax obligations upon vesting of RSUs are a common practice among corporate executives and do not necessarily indicate a negative outlook on the company's future.

Stakeholder Impact

• The sale of shares by the CFO could have a minor impact on the stock price in the short term, but is unlikely to have a significant long-term effect.

Key Dates

Keywords

Adaptive Biotechnologies, Kyle Piskel, CFO, stock sale, Form 4, tax withholding, RSUs, ADPT